The Medicines and Healthcare Products Regulatory Agency (MHRA) has published a new paper announcing its intention to overhaul the ‘rulebook’ for rare disease therapies in the UK.
Titled: “Rare therapies and UK regulatory considerations,” the paper sets out the UK’s ambition to become a global leader in developing, regulating and integrating therapies for rare diseases through a bespoke regulatory framework, whilst maintaining the safety, efficacy and sustainability of the system.
Central to the reform will be addressing the unique barriers that currently prevent life-changing rare disease therapies from reaching patients, such as small patient numbers and the challenges of generating evidence.
Highlights from the MHRA paper
- The paper targets therapies for conditions with a prevalence of ≤ 5 in 10,000 where standard clinical development programmes face major obstacles.
- A new, flexible “rare-therapy” regulatory pathway is envisaged: including adaptive trial designs (n-of-1, platform trials), use of natural-history and real-world data instead of large RCTs, conditional or stepwise approvals, and strong post-market surveillance.
- Patient and patient-representative involvement is to be embedded from the outset, with transparent communication of uncertainties and active engagement in design, evidence generation and regulatory decisions.
- International alignment and convergence are explicitly referenced: the UK intends to work with global regulatory peers to pool data and streamline evidence for therapies targeting very small patient populations.
- Health-system alignment: the paper underlines the need to coordinate regulatory, HTA (Health Technology Assessment) and NHS commissioning processes so that access to approved therapies is efficient and timely.
- Timeline: A consultation is expected early 2026, with a refined and implementable model aimed for late 2026.
Supporting the development of the reforms is a newly formed Rare Disease Consortium, which includes patients and their representatives, academics and industry.
Moving beyond ‘one-size-fits-all’
Commenting on the measures outlined in the paper, Professor Alan Boyd, Founder and CEO of Boyds said: “The MHRA’s new policy marks a transformative moment for rare disease therapies in the UK, signalling a move beyond the traditional ‘one-size-fits-all’ regulatory model. By recognising the unique challenges of small populations and advanced therapies, the MHRA is enabling more flexible, patient-focused approaches. At Boyds, we welcome this commitment and are proud to support clients developing innovative treatments that will ultimately improve outcomes and lives for people with rare diseases.”
Boyds will continue to monitor developments closely and publish regulatory updates and guidance as the framework evolves.
Looking for further advice and guidance? Get in touch with the Boyds team.